Cancer Therapy News and Research

RSS

New study addresses general barriers inhibiting cancer research commercialization

A new study led by the University of Kentucky Markey Cancer Center Assistant Director for Research Nathan Vanderford cites a combination of factors that prevent academic-based cancer research faculty from ultimately commercializing their work.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

New unique nanostructure to target drug-delivery treatment of cancer cells

A unique nanostructure developed by a team of international researchers, including those at the University of Cincinnati, promises improved all-in-one detection, diagnoses and drug-delivery treatment of cancer cells.

29 Oct 2013

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT-, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer.

29 Oct 2013

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

A self-directed walking program shows promise in easing joint stiffness in older women who experienced these symptoms while taking aromatase inhibitor therapy for breast cancer, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study confirms the "seed and soil" theory of metastasis

Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body - so-called disseminated tumor cells - are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head and neck squamous cell carcinoma cells, which remain dormant when lodged in bone marrow but rapidly form tumors when they make their way into the lungs.

28 Oct 2013

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.

25 Oct 2013

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine for its October 24, 2013 issue.

25 Oct 2013

MIT researchers design stealth drug delivery system to attack TNBC cells

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

25 Oct 2013

Rice University research reveals 3-way genetic switch for cancer metastasis

Cancer researchers from Rice University have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The study found that the on-off switch's dynamics also allows a third choice that lies somewhere between "on" and "off." The extra setting both explains previously confusing experimental results and opens the door to new avenues of cancer treatment.

25 Oct 2013

"One-two punch" disables tumors' defenses

An aggressive form of breast cancer known as "triple negative" is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs.

25 Oct 2013

Thomas Jefferson University’s interactive program discusses pros and cons of prostate cancer treatment

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program developed by Thomas Jefferson University researchers, more patients choose active surveillance over therapy, according to research being presented Wednesday (October 23rd) at the Society for Medical Decision Making annual meeting in Baltimore, Maryland.

24 Oct 2013

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Patient assistance programs can help breast cancer patients meet a variety of needs that can interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of the Journal of Oncology Practice.

24 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.

23 Oct 2013

Risk for breast cancer: Key prevention awareness tips for young women

Breast cancer prevention needs to become a shared conversation among women of all ages as it can strike at any age, and is generally more aggressive when diagnosed in women under the age of 50. With hopes to spark that discussion, Isabelle Mercier, PhD, a research assistant professor at University of the Sciences, compiled some key prevention awareness tips for young women.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

Cancer Therapy News and Research

New study addresses general barriers inhibiting cancer research commercialization

Immune Design closes Series C financing totalling up to $49M

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

New unique nanostructure to target drug-delivery treatment of cancer cells

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

Study confirms the "seed and soil" theory of metastasis

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

MIT researchers design stealth drug delivery system to attack TNBC cells

Rice University research reveals 3-way genetic switch for cancer metastasis

"One-two punch" disables tumors' defenses

Thomas Jefferson University’s interactive program discusses pros and cons of prostate cancer treatment

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

Risk for breast cancer: Key prevention awareness tips for young women

Study opens doors to novel treatments for aggressive brain cancer

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News